 InPharm | Indian CMO will make Roche blockbusters InPharm Meanwhile, a separate report in the Economic Times has suggested that the deal could also be extended to cover Roche's non-Hodgkin's lymphoma therapy MabThera/Rituxan (rituximab). The deal is a major coup for Emcure, which has already chalked up a ... |
